<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347931</url>
  </required_header>
  <id_info>
    <org_study_id>CP-00-0034</org_study_id>
    <nct_id>NCT01347931</nct_id>
  </id_info>
  <brief_title>In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency</brief_title>
  <official_title>In-home Evaluation of the Breathe Technologies Noninvasive Open Ventilation (NIOV™) System in Patients With Severe Respiratory Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Breathe Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Breathe Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Breathe NIOV™ System will reduce the work of breathing in subjects with chronic
      respiratory insufficiency who require long-term oxygen therapy (LTOT). The Breathe system
      will accomplish this by providing oxygen under pressure and augmenting the subject's
      spontaneous tidal volumes. The combination of efficient oxygen delivery, assisted
      ventilation, and a comfortable low-profile device, will result in a mean improvement in
      perceived well-being and ability to perform ADLs, as measured by patient-reported outcome
      (PRO) instruments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, open-label, crossover study in up to 12 stable subjects with
      chronic respiratory insufficiency who require LTOT. Each subject's standard oxygen therapy
      will be used as the control treatment and compared to the test ventilator system during
      selected activities of daily living. Subjects will participate in the study for up to 9 home
      visits, with Visits 1 and 2 each lasting for approximately 4 hours, and Visits 3-9 lasting
      approximately 1-2 hours each. Subjects may discontinue study participation at any time.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Activity Endurance Time</measure>
    <time_frame>Measured during single day study visit</time_frame>
    <description>Time in minutes of sustained activity while using test treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial Oxygen Saturation</measure>
    <time_frame>Measured during activity testing in a single day study visit</time_frame>
    <description>O2 saturation measured by pulse oximetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg Dyspnea Score</measure>
    <time_frame>Measured during activity testing in a single day study visit</time_frame>
    <description>Borg Dyspnea score is measured using a 11-point visual analog scale. The lower the score on the scale, the less breathlessness patient experiences. The score ranges from:
0 = No breathlessness at all, representing better outcome 10 = Maximum, representing worse outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <condition>Airflow Obstruction, Chronic</condition>
  <condition>Chronic Obstructive Airway Disease</condition>
  <condition>Chronic Obstructive Lung Disease</condition>
  <arm_group>
    <arm_group_label>NIOV System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Noninvasive ventilation and oxygen delivered via NIOV System oxygen using an open nasal interface. Connected to standard portable oxygen cylinder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Oxygen Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Supplemental oxygen using standard oxygen cannula connected to a portable oxygen cylinder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NIOV System</intervention_name>
    <description>Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.</description>
    <arm_group_label>NIOV System</arm_group_label>
    <other_name>NIOV</other_name>
    <other_name>Oxygen</other_name>
    <other_name>O2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard Oxygen Cannula</intervention_name>
    <description>Supplemental oxygen via a standard oxygen cannula connected to a portable oxygen cylinder</description>
    <arm_group_label>Standard Oxygen Therapy</arm_group_label>
    <other_name>Cannula</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male and female subjects, 21-80 years of age

          -  Diagnosis of chronic respiratory insufficiency including COPD and interstitial lung
             disease

          -  Requires use of continuous nasal oxygen of at least 2 lpm

          -  Reports limitation of activity due to fatigue or breathlessness

          -  Fluent in written and spoken English language

          -  Ability to be properly fitted with the Breathe nasal mask

          -  Ability to tolerate and be appropriately titrated on the Breathe ventilator

          -  Ability to communicate self-assessment of dyspnea, comfort, and fatigue

          -  Ability and willingness to participate in the study including walking and other
             activities of daily living

          -  Ability to provide written informed consent

        Exclusion Criteria:

          -  Recent history of frequent or severe epistaxis

          -  Symptoms of acute respiratory exacerbation within 48 hours of Study Day 1

          -  Discharge from the hospital within 30 days of study enrollment

          -  Subjects, who in the opinion of the Investigator, are not suitable candidates for
             enrollment or who are unlikely to be able to comply with trial requirements

          -  Subjects with conditions that, in the Investigator's opinion, contraindicates study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian W Carlin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Penn Allegheny Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <results_first_submitted>March 8, 2015</results_first_submitted>
  <results_first_submitted_qc>August 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 11, 2016</results_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Oxygen Therapy</title>
          <description>Supplemental oxygen delivered via standard nasal cannula connected to a portable oxygen cylinder.
Breathe NIOV System: Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Standard Oxygen Therapy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>NIOV System</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Per protocol</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study Group</title>
          <description>All subjects participating in 2-way crossover design study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Activity Endurance Time</title>
        <description>Time in minutes of sustained activity while using test treatments</description>
        <time_frame>Measured during single day study visit</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Oxygen Therapy</title>
            <description>Supplemental oxygen delivered via standard nasal cannula connected to a portable oxygen cylinder.
NIOV System: Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.</description>
          </group>
          <group group_id="O2">
            <title>Breathe NIOV System</title>
            <description>Noninvasive ventilation delivered via NIOV System oxygen using an open nasal interface. Connected to standard portable oxygen cylinder
NIOV System: Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.</description>
          </group>
        </group_list>
        <measure>
          <title>Activity Endurance Time</title>
          <description>Time in minutes of sustained activity while using test treatments</description>
          <population>Per Protocol</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.24" spread="5.21"/>
                    <measurement group_id="O2" value="13.38" spread="7.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A sample size of 26 patient pairs was determined based on the assumption of a true treatment difference in mean ADL endurance time of 4 ± 7 minutes using a two-tailed, paired t test (α=0.05, power=0.80).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arterial Oxygen Saturation</title>
        <description>O2 saturation measured by pulse oximetry</description>
        <time_frame>Measured during activity testing in a single day study visit</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Oxygen Therapy</title>
            <description>Supplemental oxygen delivered via standard nasal cannula connected to a portable oxygen cylinder.
NIOV System: Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.</description>
          </group>
          <group group_id="O2">
            <title>Breathe NIOV System</title>
            <description>Noninvasive ventilation delivered via NIOV System oxygen using an open nasal interface. Connected to standard portable oxygen cylinder
NIOV System: Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.</description>
          </group>
        </group_list>
        <measure>
          <title>Arterial Oxygen Saturation</title>
          <description>O2 saturation measured by pulse oximetry</description>
          <population>Per Protocol</population>
          <units>percentage of oxyHb saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.65" spread="4.87"/>
                    <measurement group_id="O2" value="94.78" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Two-tailed t test</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Borg Dyspnea Score</title>
        <description>Borg Dyspnea score is measured using a 11-point visual analog scale. The lower the score on the scale, the less breathlessness patient experiences. The score ranges from:
0 = No breathlessness at all, representing better outcome 10 = Maximum, representing worse outcome</description>
        <time_frame>Measured during activity testing in a single day study visit</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Oxygen Therapy</title>
            <description>Supplemental oxygen delivered via standard nasal cannula connected to a portable oxygen cylinder.
NIOV System: Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.</description>
          </group>
          <group group_id="O2">
            <title>Breathe NIOV System</title>
            <description>Noninvasive ventilation delivered via NIOV System oxygen using an open nasal interface. Connected to standard portable oxygen cylinder
NIOV System: Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.</description>
          </group>
        </group_list>
        <measure>
          <title>Borg Dyspnea Score</title>
          <description>Borg Dyspnea score is measured using a 11-point visual analog scale. The lower the score on the scale, the less breathlessness patient experiences. The score ranges from:
0 = No breathlessness at all, representing better outcome 10 = Maximum, representing worse outcome</description>
          <population>Per Protocol</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2.80" upper_limit="4.07"/>
                    <measurement group_id="O2" value="1" lower_limit="1.00" upper_limit="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Continuously monitored during a Single day study visit lasting up to 4 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Oxygen Therapy</title>
          <description>Supplemental oxygen delivered via standard nasal cannula connected to a portable oxygen cylinder.
NIOV System: Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.</description>
        </group>
        <group group_id="E2">
          <title>Breathe NIOV System</title>
          <description>Noninvasive ventilation delivered via NIOV System oxygen using an open nasal interface. Connected to standard portable oxygen cylinder
NIOV System: Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard J. Morishige, MS, RRT</name_or_title>
      <organization>Clinical Reseach Consulting</organization>
      <phone>510-606-0375</phone>
      <email>rjmorishige@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

